Chemo plus two targeted drugs before surgery for HER2+ breast cancer
Part of Cancer clinical trials.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- Your breast cancer is HER2-positive (a specific protein that helps cancer grow).
- Your cancer is at an early stage that has not spread to other organs (Stage I–III, node-positive or larger tumors).
- You have not received prior anti-cancer treatment for this breast cancer.
- Your heart, kidney, and liver function are within normal limits, and you have no serious heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial tests a combination of targeted drugs (Initumab and Pyrrotinib) plus chemotherapy before surgery for HER2-positive breast cancer. It compares different treatment lengths to see which is more effective and safe.
This Phase 2 trial studies a second anti-HER2 treatment (given after surgery) to help lower the risk of breast cancer coming back in people with very small, node-negative, HER2-positive tumors. It will also closely monitor heart function and other side effects because these medicines can affect the body.
This trial tests a targeted drug called pyrotinib for women with HER2-positive early or locally advanced breast cancer. It aims to see if adding this treatment before surgery improves outcomes.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.